Comprehensive Cancer Centers’ Dr. Souzan El-Eid Named to National Breast Cancer Committee

By May 18, 2018 May 23rd, 2018 Press Release, Recognition

Souzan El-Eid, MD, FACS – a breast surgeon at Comprehensive Cancer Centers – was recently named to a prestigious committee within the American Society of Breast Surgeons.

At the organization’s annual meeting in Orlando, Dr. El-Eid was announced as the new chair of the Breast Imaging Technologies Certification and Accreditation Committee (BITCAC), to which there is no term limit to the position. Leading the committee, Dr. El-Eid will help individual surgeons and facilities achieve vital accreditations, signifying key standards and a level of quality in breast surgery.

Dr. El-Eid sees patients at Comprehensive’s Southwest Breast Surgery Treatment Center, located at 9280 W. Sunset Road, Suite 100, Las Vegas, NV, 89148.

Additionally, at Summerlin Hospital, she serves as the Medical Director of the Breast Care Center; the Cancer Liaison Physician for the Cancer Program; and co-chair of the Breast Tumor Board and Cancer Committee. Dr. El-Eid is an Adjunct Associate Professor of General Surgery at Touro University Nevada; is a UNLV School of Medicine clinical assistant professor; and has served as principal investigator for several clinical research studies. She is also past President of Clark County Medical Society.

About Comprehensive Cancer Centers of Nevada

Comprehensive Cancer Centers (Comprehensive) is an award-winning multidisciplinary practice comprising medical oncology, hematology, radiation oncology, breast surgery, pulmonary services, cancer genetic counseling and clinical research, with treatment centers and offices throughout Southern Nevada. For more than 35 years, the practice has provided oncology services to patients in and out of state with a specialized physician and nursing staff. Comprehensive, an affiliate of The US Oncology Network, offers state-of-the-art technologies, latest advancements in cancer treatment and groundbreaking clinical research trails. The practice participates in more than 170 Phase I, Phase II and Phase III clinical research studies each year and has played a role in developing more than 70 FDA-approved cancer therapies. For more information, visit the company’s website at, and follow the practice on Facebook, Twitter and Instagram.